Aaron Kantoff - Insider Trading & Ownership

Location
C/O Centessa Pharmaceuticals Plc, D. Hodgkin Bldg, Babraham Rsrch Campus, Cambridge, United Kingdom
Summary
The estimated net worth of Aaron Kantoff is at least $1.44M dollars as of September 9, 2025. Aaron Kantoff is the Director of Tourmaline Bio, Inc. and owns shares of Tourmaline Bio, Inc. (TRML) stock worth about $882K. Aaron Kantoff is the Director of Centessa Pharmaceuticals plc and owns shares of Centessa Pharmaceuticals plc (CNTA) stock worth about $478K. Aaron Kantoff is the Director of Avalo Therapeutics, Inc. and owns shares of Avalo Therapeutics, Inc. (AVTX) stock worth about $80.4K.
Signature
/s/ Brad Middlekauff, Attorney-in-Fact
All Insider Reports
All Insider Reports

Ownership of Aaron Kantoff

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
TRML Tourmaline Bio, Inc. Director $882K Sep 5, 2025
CNTA Centessa Pharmaceuticals plc Director $478K Nov 18, 2021
AVTX Avalo Therapeutics, Inc. Director $80.4K Jun 17, 2025

Insider Transactions Reported by Aaron Kantoff:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.